{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T08:36:37Z","timestamp":1790670997640,"version":"4.1.0"},"reference-count":30,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2009,2,7]],"date-time":"2009-02-07T00:00:00Z","timestamp":1233964800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Allergy"],"published-print":{"date-parts":[[2009,6]]},"abstract":"<jats:p><jats:bold>Background:\u2002<\/jats:bold> The Fip1\u2010like\u20101\u2013platelet\u2010derived growth factor receptor alpha (FIP1L1\u2010PDGFRA) gene fusion is a common cause of chronic eosinophilic leukemia (CEL)\/hypereosinophilic syndrome (HES), and patients suffering from this particular subgroup of CEL\/HES respond to low\u2010dose imatinib therapy. However, some patients may develop imatinib resistance because of an acquired T674I mutation, which is believed to prevent drug binding through steric hindrance.<\/jats:p><jats:p><jats:bold>Methods:\u2002<\/jats:bold> In an imatinib resistant FIP1L1\u2010PDGFRA positive patient, we analyzed the molecular structure of the fusion gene and analyzed the effect of several kinase inhibitors on FIP1L1\u2010PDGFRA\u2010mediated proliferative responses <jats:italic>in vitro<\/jats:italic>.<\/jats:p><jats:p><jats:bold>Results:\u2002<\/jats:bold> Sequencing of the FIP1L1\u2010PDGFRA fusion gene revealed the occurrence of a S601P mutation, which is located within the nucleotide binding loop. In agreement with the clinical observations, imatinib did not inhibit the proliferation of S601P mutant FIP1L1\u2010PDGFRA\u2010transduced Ba\/F3 cells. Moreover, sorafenib, which has been described to inhibit T674I mutant FIP1L1\u2010PDGFRA, failed to block S601P mutant FIP1L1\u2010PDGFRA. Structural modeling revealed that the newly identified S601P mutated form of PDGFRA destabilizes the inactive conformation of the kinase domain that is necessary to bind imatinib as well as sorafenib.<\/jats:p><jats:p><jats:bold>Conclusions:\u2002<\/jats:bold> We identified a novel mutation in FIP1L1\u2010PDGFRA resulting in both imatinib and sorafenib resistance. The identification of novel drug\u2010resistant FIP1L1\u2010PDGFRA variants may help to develop the next generation of target\u2010directed compounds for CEL\/HES and other leukemias.<\/jats:p>","DOI":"10.1111\/j.1398-9995.2009.01943.x","type":"journal-article","created":{"date-parts":[[2009,2,7]],"date-time":"2009-02-07T09:33:16Z","timestamp":1233999196000},"page":"913-918","source":"Crossref","is-referenced-by-count":21,"title":["A novel FIP1L1\u2010PDGFRA mutant destabilizing the inactive conformation of the kinase domain in chronic eosinophilic leukemia\/hypereosinophilic syndrome"],"prefix":"10.1111","volume":"64","author":[{"given":"S.","family":"Salemi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Yousefi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Simon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Schmid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Moretti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Scapozza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.\u2010U.","family":"Simon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2009,5,11]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2007.02.010"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa025217"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)08505-7"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-08-2798"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.20088"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0932698100"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403600"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2006.06221.x"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1062538"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2007.11.027"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm.1855"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1002\/eji.200635943"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20032033"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.12212"},{"key":"e_1_2_5_16_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-02-004457"},{"key":"e_1_2_5_17_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M403319200"},{"key":"e_1_2_5_18_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.C300186200"},{"key":"e_1_2_5_19_2","doi-asserted-by":"publisher","DOI":"10.1006\/jmbi.1993.1626"},{"key":"e_1_2_5_20_2","doi-asserted-by":"publisher","DOI":"10.1002\/jcc.20291"},{"key":"e_1_2_5_21_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10822-004-3752-4"},{"key":"e_1_2_5_22_2","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/16.2.135"},{"key":"e_1_2_5_23_2","unstructured":"DeLanoWL.The pymol molecular graphics system. Available at:http:\/\/www.pymol.org\/ 2003."},{"key":"e_1_2_5_24_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa040938"},{"key":"e_1_2_5_25_2","first-page":"4236","article-title":"Crystal structures of the kinase domain of c\u2010Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI\u2010571)","volume":"62","author":"Nagar B","year":"2002","journal-title":"Cancer Res"},{"key":"e_1_2_5_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(04)00215-6"},{"key":"e_1_2_5_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1097-2765(03)00505-7"},{"key":"e_1_2_5_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmb.2007.01.036"},{"key":"e_1_2_5_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(03)00190-9"},{"key":"e_1_2_5_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(03)00979-3"},{"key":"e_1_2_5_31_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-05-2788"}],"container-title":["Allergy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1398-9995.2009.01943.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1398-9995.2009.01943.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T04:14:01Z","timestamp":1697429641000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1398-9995.2009.01943.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,5,11]]},"references-count":30,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2009,6]]}},"alternative-id":["10.1111\/j.1398-9995.2009.01943.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1398-9995.2009.01943.x","archive":["Portico"],"relation":{},"ISSN":["0105-4538","1398-9995"],"issn-type":[{"value":"0105-4538","type":"print"},{"value":"1398-9995","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,5,11]]}}}